(Q33794098)

English

GLP-1 for type 2 diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

GLP-1 for type 2 diabetes (English)

1 reference

Europe PubMed Central

29 July 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

object named as

Bo Ahrén

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

13 January 2011

1 reference

Europe PubMed Central

29 July 2017

Experimental Cell Research

1 reference

Europe PubMed Central

29 July 2017

317

1 reference

Europe PubMed Central

29 July 2017

9

1 reference

Europe PubMed Central

29 July 2017

1239-1245

1 reference

Europe PubMed Central

29 July 2017

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Mechanisms of action of glucagon-like peptide 1 in the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

The role of GLP-1 in the life and death of pancreatic beta cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Emerging treatment options for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Association of pancreatitis with glucagon-like peptide-1 agonist use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

7 January 2021

Identifiers

10.1016/J.YEXCR.2011.01.010

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33794098&oldid=1953670298"